Why Syndax Pharmaceuticals Inc. (SNDX) stock is decreasing rapidly?

Syndax Pharmaceuticals, Inc. (SNDX), a clinical-stage healthcare company that focuses on an HDAC inhibitor for tumors and specializes in cancer therapies, announced the latest positive data from Phase 1 of the trial inclusive of the dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia. SNDX stock […]